FDCHDPi001-A

FDCHDP01

General

Cell Line

hPSCreg name FDCHDPi001-A
Cite as:
FDCHDPi001-A (RRID:CVCL_A9ZP)
Alternative name(s)
FDCHDP01
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
USPi001-A
(iPS_LGH_AHDC1_P1)
Donor's gene variants:
AHDC1
Donor diseases:
Xia-Gibbs Syndrome
USPi002-A
(iPS_LGH_AHDC1_P2)
Donor's gene variants:
AHDC1
Donor diseases:
Xia-Gibbs Syndrome
USPi003-A
(iPS_LGH_AHDC1_P3)
Donor's gene variants:
AHDC1
Donor diseases:
Xia-Gibbs Syndrome
IMBAi016-A
(B001-ARID1B#10, Pat.1 ARID1B+/- clone 1a (XY))
Donor diseases:
Coffin-Siris syndrome
Last update 17th October 2022
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Fudan University (FDCHDP)
Owner Children’s Hospital of Fudan University (FDCH)
Distributors
Derivation country China

External Databases

Cellosaurus CVCL_A9ZP
BioSamples SAMEA8342010
Wikidata Q102113814

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Cell line can only be used in: biology
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Additional restrictions:

no

Donor Information

General Donor Information

Sex male
Age of donor (at collection) 10-14
Ethnicity Chinese Han

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Tourette syndrome
The donor is affected.
Stage
having suffered tourette syndrome for 4 years
Synonyms
  • Tourette's Syndrome
  • Tourette Syndrome
  • Gilles de la Tourette syndrome
Genetic variants
Please explain briefly the supporting evidence
Disease associated phenotypes
  • chronic motor and vocal tics
  • heritable neurological disorder
Family history The donor's father also suffers from Tourette syndrome.
Is the medical history available upon request? The medical history will be available upon request by the user of the cell line.
Is clinical information available? The clinical information will be available upon request by the user of the cell line.

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
46, xy
Karyotyping method: G-Banding

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA7059987

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Yes
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? Yes
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a for-profit corporation? No
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? Yes
Does consent permit access to medical records of the donor? Yes
Please describe how access is provided:
Does consent permit access to any other source of information about the clinical treatment or health of the donor? Yes
Contact data, institution, or website:
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Ethics Committee of childre's hospital of Fudan University
Approval number (2019) 308
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? Ethics Committee of childre's hospital of Fudan University
Approval number (2019) 308
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type
A leukocyte with a single non-segmented nucleus in the mature form found in the circulatory pool of blood.
Source cell origin
Synonyms
  • Peripheral blood monocyte
Source cell line lot number
STD003P
Age of donor (at collection) 10-14
Collected in 2019
Passage number reprogrammed 16

Reprogramming method

Vector type Non-integrating
Vector Episomal
Is reprogramming vector detectable?
No
Methods used
PCR
Files and images showing reprogramming vector expressed or silenced
Vector map

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Selection criteria for clones expressing SOX2, NANOG, TRA-1-60 and OCT4
Derived under xeno-free conditions
Unknown
Derived under GMP?
Yes
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells Mouse Embryonic Fibroblast
Passage method Enzymatically
Collagenase
O2 Concentration 21 %
CO2 Concentration 5 %
Medium Other medium:
Base medium: Dulbecco's Modified Eagle's Medium F-12 Ham
Main protein source: Knock-out serum replacement
Serum concentration: 20 %
Supplements
MEM Non-Essential Amin Acids Solution 1 %
GlutaMAXTM-1 1 %
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
SOX2
Yes
NANOG
Yes
TRA 1-60
Yes
POU5F1 (OCT-4)
Yes
Self-renewal
Positive
Endoderm
Positive
Mesoderm
Positive
Ectoderm score
Positive
Differentiation Potency
Digestive Tract Epithelium
Ont Id: UBERON_0003929
In vivo teratoma
Morphology
Cartilage Element
Ont Id: UBERON_0007844
In vivo teratoma
Morphology
Neuroepithelial Stem Cell
Ont Id: CL_0002259
In vivo teratoma
Morphology

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,xy
Passage number: 16
Karyotyping method: G-Banding

Other Genotyping (Cell Line)